KB
Therapeutic Areas
MapLight Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ML-007 | Social impairment in Autism Spectrum Disorder | Phase 2 |
| ML-104 | Treatment-resistant Depression | Preclinical |
| ML-225 | Cognitive impairment in Alzheimer's Disease | Preclinical |
| Undisclosed Program | Anxiety Disorders | Discovery |
Leadership Team at MapLight Therapeutics
CG
Christopher G. Verni, Ph.D.
Chief Executive Officer
DL
David L. Gray, Ph.D.
Chief Scientific Officer
MA
M. Amin Khan, Ph.D.
Chief Development Officer
SB
Sarah B. Noonberg, M.D., Ph.D.
Chief Medical Officer
JA
James A. Johnson, CPA
Chief Financial Officer
MD
Megan D. Schmidt, J.D.
Chief Business Officer and General Counsel
RA
Richard A. Scheller, Ph.D.
Chairman of the Board of Directors
BE
Bryan E. Roberts, Ph.D.
Director
BS
Beth Seidenberg, M.D.
Director
KA
Katherine A. High, M.D.
Director